Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398189 | 0.82 | ADAMTS5 (0.43) | RAB9AALDH1A1L3MBTL1SMN1; SMN2ADAMTS5 | |
| SCHEMBL874455 | 0.82 | ADAMTS5 (0.54) | RAB9AALDH1A1L3MBTL1LMNAMEN1 | |
| SCHEMBL9659322 | 0.81 | RAB9A (0.42) | RAB9AALDH1A1L3MBTL1LMNAMEN1 | |
| SCHEMBL3440132 | 0.80 | KDM4E (0.43) | RAB9AALDH1A1L3MBTL1LMNAMEN1 | |
| SCHEMBL1846533 | 0.80 | RAB9A (0.41) | RAB9AALDH1A1L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL1398316 | 0.79 | ADAMTS5 (0.42) | RAB9AALDH1A1L3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL13208839 | 0.78 | HSD17B10 (0.45) | RAB9AALDH1A1LMNAMEN1HTT | |
| SCHEMBL7381763 | 0.78 | ADAMTS5 (0.44) | RAB9AALDH1A1L3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL11985535 | 0.78 | ADAMTS5 (0.41) | RAB9AALDH1A1L3MBTL1MEN1SMN1; SMN2 | |
| SCHEMBL27737137 | 0.78 | ALDH1A1 (0.53) | RAB9AALDH1A1L3MBTL1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729066-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | claimed |
| EP-1450796-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045385-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | claimed |
| WO-2023165551-A1 | SIX-MEMBERED AROMATIC RING-PYRROLIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-115677692-A | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114025756-B | Phosphatidylinositol 3-kinase inhibitors | 南京征祥医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-105254585-A | Thiazole amide compound and preparation method and application thereof | UNIVTAISHAN MEDICAL | 2016-01-20 | — | — | CN | disclosed |
| CN-103889963-A | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RES INST | 2014-06-25 | — | — | CN | disclosed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | disclosed |
| US-8163761-B2 | Methods and compositions for treating disorders | HYDRA BIOSCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
| WO-2003018546-A2 | TRICYCLIC PYRIDIN-2-ONE ANALOGUES AS LIGANDS FOR GABA-A RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-03-06 | — | — | WO | disclosed |
| US-6352994-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| US-20010053776-A1 | Tricyclic pyridin-2-one analogue as a GABA receptor ligand | CRAWFORTH JAMES MICHAEL (GB) | 2001-12-20 | — | — | US | disclosed |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | MERCK SHARP & DOHME LIMITED | 2001-08-30 | — | — | US | disclosed |
| US-6200982-B1 | USEFUL IN THERAPY OF DELETERIOUS MENTAL STATES | MERCK & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-6133255-A | Tricyclic pyridone analogues as GABA-A receptor ligands | MERCK SHARP & DOHME LIMITED (GB) | 2000-10-17 | — | — | US | disclosed |
| EP-0994873-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998055480-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABAAALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053776-A1 | Tricyclic pyridin-2-one analogue as a GABA receptor ligand | GABRA2, GABRA3, GABRA4 | RAB9A 3063/4885ALDH1A1 549/4885L3MBTL1 959/4885 |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | GABRB2, GABRB3, GABRB1 | RAB9A 1291/4885ALDH1A1 484/4885L3MBTL1 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.